<DOC>
	<DOCNO>NCT01887613</DOCNO>
	<brief_summary>This study investigate long-term safety efficacy information proper use Regnite® condition daily clinical use .</brief_summary>
	<brief_title>Specified Drug Use-Results Survey Regnite</brief_title>
	<detailed_description>Sleeping condition severity restless legs syndrome ( RLS ) record start treatment . The treatment period schedule last 52 week principle . For patient complete discontinue use Regnite® within 52 week , follow withdrawal rebound syndrome conduct 4 week completion discontinuation .</detailed_description>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<criteria>Patients moderate severe idiopathic restless legs syndrome Patients history hypersensitivity ingredient Regnite gabapentin Patients severely impair renal function ( creatinine clearance le 30 mL/min )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gabapentin</keyword>
</DOC>